Wearable Large Volume Injectors Hold Promise for Success in Commercialization of Biologics

Michael D. Hooven
Enable Injections Inc.
Jeannie Joughin

DOI:https://doi.org/10.5912/jcb805

Abstract:

With so many biologics in development and no patient-centric way to deliver them, it was inevitable that innovative delivery solutions would emerge that enable a new pharmaceutical product to meet two top criteria for successful commercialization: satisfy patient demands for easy drug administration without disruption to their everyday lives, and address health system demands for lower costs and more value. The solution lies in combining biologic drugs with the more advanced large volume wearable injectors to enable patients to self-inject even the most viscous formulations and volumes of up to 50 mL with ease and comfort in their homes or workplaces.

Keywords:Large volume wearable injectors ,combination products ,biologics ,drug delivery ,cancer ,autoimmune diseases ,viscosity ,formulation ,rare diseases ,self-administration ,subcutaneous injections ,patient-centricity ,en ,